Rachael

Stovall

MD, MAS

EDUCATION & TRAINING: 

BS, University of Washington, Seattle (2006-2010)

Fulbright Fellow, Amman, Jordan (2010-2011)

MD, University of Washington, Seattle (2013-2017)

Residency, Boston University Medical Center (2017-2020)

Fellowship, University of California San Francisco (2020-2023)

MAS, University of California San Francisco (2021-2023)

RESEARCH INTERESTS: 

Dr. Stovall is an academic rheumatologist and clinical researcher whose research focuses on outcomes in spondyloarthritis. She uses large observational datasets, including electronic health record data, to answer important questions that cannot be answered by clinical trials due to the need for larger numbers of patients followed over longer periods of time. She is currently studying sex differences related to clinically important outcomes among patients with spondyloarthritis. She is a member of the Spondyloarthritis Research and Treatment Network (SPARTAN) and Assessment of SpondyloArthritis international Society (ASAS).

MY NCBI: 

My NCBI Bibliography

PUBLICATIONS: 

Palmowski A, Roberts E, Li J, Kersey E, Stovall R, Buttgereit F, Yazdany J, and Schmajuk G. “Initiation of Glucocorticoids before Entering Rheumatology Care Associates with Long-Term Glucocorticoid Use in Older Adults with Early Rheumatoid Arthritis: A Joint Analysis of Medicare and the Rheumatology Informatics System for Effectiveness (RISE) Data.” Seminars in Arthritis and Rheumatism 68 (August 22, 2024): 152535. https://doi.org/10.1016/j.semarthrit.2024.152535.

Palmowski A, Schmajuk G, Yazdany J, Katz P, Li J, Stovall R, Kersey E, Nielsen S, Christensen R, Bliddal H, Boyadzhieva Z, Schneider U, Alexander T, Muche B, Hermann S, Wiebe E, Buttgereit F. “Proton Pump Inhibitor Use and Bone Health in Patients With Rheumatic Diseases: A Cross-Sectional Study.” Mayo Clinic Proceedings 99, no. 7 (July 2024): 1046–57. https://doi.org/10.1016/j.mayocp.2023.12.008.

Liew J, Treu T, Park Y, Ferguson J, RosserM, Ho Y, Gagnon D, Stovall R, Monach P, Heckbert S, Gensler L, Liao K, Dubreuil M. The association of TNF inhibitor use with incident cardiovascular events in radiographic axial spondyloarthritis. Seminars in Arthritis and Rheumatism 68 (June 2, 2024): 152482. https://doi.org/10.1016/j.semarthrit.2024.152482.

Stovall R, Kersey E, Li J, Baker R, Anastasiou C, Palmowski A, Schmajuk G, Gensler L, Yazdany J. “Incidence Rate and Factors Associated With Fractures Among Medicare Beneficiaries With Ankylosing Spondylitis in the United States.” Arthritis Care & Research 76, no. 2 (February 2024): 265–73. https://doi.org/10.1002/acr.25219.

Stovall R, van der Horst-Bruinsma IE, Liu SH, Rusman T, Gensler LS. “Sexual Dimorphism in the Prevalence, Manifestation and Outcomes of Axial Spondyloarthritis.” Nature Reviews. Rheumatology 18, no. 11 (November 2022): 657–69. https://doi.org/10.1038/s41584-022-00833-0.

Stovall R, Peloquin C, Felson D, Neogi T, Dubreuil M. “Relation of NSAIDs, DMARDs, and TNF Inhibitors for Ankylosing Spondylitis and Psoriatic Arthritis to Risk of Total Hip and Knee Arthroplasty.” The Journal of Rheumatology 48, no. 12 (December 2021): 1892. https://doi.org/10.3899/jrheum.200453.C1.

Stovall R, Peloquin C, Felson D, Neogi T, Dubreuil M. “Relation of Therapies for Ankylosing Spondylitis and Psoriatic Arthritis to Risk of Myocardial Infarction: A Nested Case Control Study.” BMC Rheumatology 5, no. 1 (July 29, 2021): 36. https://doi.org/10.1186/s41927-021-00207-1.